Europe resumes use of J&J COVID-19 vaccine after EMA review

By The Science Advisory Board staff writers

April 21, 2021 -- Rollout of the COVID-19 vaccine from Johnson & Johnson will resume after the European Medicines Agency (EMA) confirmed that the vaccine's overall benefit-risk profile remains positive.

The agency updated its use guidance after its Pharmacovigilance Risk Assessment Committee (PRAC) completed a review of a small number of cases of very rare adverse events involving blood clots in combination with low platelet counts. The events occurred within approximately one to three weeks of being vaccinated.

The company will resume shipment of the Janssen COVID-19 vaccine in the European Union, Norway, and Iceland.

Cidara partners with Janssen to develop antiviral conjugates
Cidara Therapeutics has inked a $780 million exclusive global rights agreement with Janssen Pharmaceuticals for Cidara's Cloudbreak antiviral conjugates...
Takeda, IDT help manufacture Janssen COVID-19 vaccine
Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.
Janssen COVID-19 vaccine authorized in EU
Just hours after receiving a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use on March 11,...
Janssen COVID-19 vaccine issued WHO authorization
Johnson & Johnson has been issued an emergency use listing by the World Health Organization (WHO) for the Janssen single-shot COVID-19 vaccine to...
Merck gets $269M to ramp up COVID-19 vaccine manufacturing
Merck has received about $269 million in U.S. funding to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 vaccines and medicines.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter